|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:affiliatedWith
|
checkpoint inhibitors
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:Japan
gptkb:FDA
gptkb:squamous_cell_carcinoma_of_the_head_and_neck
gptkb:classical_Hodgkin_lymphoma
2014
colorectal cancer
esophageal cancer
melanoma
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:ATCCode
|
L01XC17
|
|
gptkbp:brand
|
gptkb:Opdivo
|
|
gptkbp:CASNumber
|
946414-94-4
|
|
gptkbp:combinationTherapy
|
gptkb:ipilimumab
|
|
gptkbp:contraindication
|
hypersensitivity to nivolumab
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discoveredBy
|
gptkb:Ono_Pharmaceutical
|
|
gptkbp:halfLife
|
25 days
|
|
gptkbp:hasMolecularFormula
|
C6368H9864N1712O1996S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nivolumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
advanced cancers
adjuvant therapy
metastatic cancers
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
blocks PD-1 receptor
enhances T-cell response
|
|
gptkbp:monitors
|
immune-related adverse events
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
hepatitis
rash
inflammatory bowel disease
endocrinopathies
immune-mediated pneumonitis
|
|
gptkbp:target
|
gptkb:PD-1
|
|
gptkbp:UNII
|
QDL4442L0U
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|